This site is intended for healthcare professionals
Improving patient outcomes in chronic spontaneous urticaria
CSU Learning Zone
Declaration of sponsorship Novartis Pharma AG

Industry-Sponsored Symposia

Declaration of sponsorship Novartis Pharma AG
Read time: 290 mins
Last updated:15th Jun 2023
Published:29th Oct 2021

Get up to date with the latest scientific information about chronic spontaneous urticaria (CSU):

  • Watch the symposia from EAACI and EADV 2022 annual congresses

  • Hear from world-leading experts in the field of chronic spontaneous urticaria

Novartis-sponsored satellite symposium - Reimagining immunology: The path to optimized management of chronic spontaneous urticaria

In September 2022, the European Academy of Dermatology and Venereology (EADV) celebrated their Annual Congress in a ‘hybrid’ format

This year’s Novartis company-sponsored symposium entitled “Reimagining immunology: The path to optimized management of chronic spontaneous urticaria”, was chaired by dermatologist Professor Marcus Maurer alongside two international urticaria experts, Professor Silvia Ferrucci and Professor Simon Francis Thomsen. In this 1-hour symposium, the faculty explored ways to help overcome barriers to improved management of chronic spontaneous urticaria (CSU). Case studies, combined with clinical and real-world evidence, illustrated the path towards the optimized management of CSU patients, with the goal of complete response.

Watch the full symposium video below. Use the chaptering buttons within the video to navigate to each section.

Video contents

Chapter 1: Welcome address (00:00–03:45)

Chapter 2: Introduction with Professor Maurer (03:46–10:31)

Chapter 3: Roadblocks encountered before the patient gets the correct diagnosis (10:32–22:00)

Chapter 4: Roadblocks accessing the correct treatment after diagnosis (22:01–37:07)

Chapter 5: Roadblocks on the way towards treatment optimization (37:08–50:35)

Chapter 6: Roadblocks encountered while approaching complete control of CSU (50:35–1:01:07)

Chapter 7: Closure (1:01:08– end)

Meet the experts

Professor Marcus Maurer Marcus Maurer.png

Marcus Maurer is Professor of Dermatology and Allergy, Head of the Institute of Allergology at Charité – Universitätsmedizin Berlin and Immunology and Allergology at the Fraunhofer Institute of Translational Medicine and Pharmacology, both in Berlin, Germany. He is Head of the Specialty Clinics for Urticaria, Mastocytosis, Pruritus and Angioedema, and the Dermatological Allergology Lab. Professor Maurer has co-authored >660 publications in peer-review journals, and 45 books and book chapters. 

Disclosures

This symposium is organised and funded by Novartis Pharma AG, Professor Marcus Maurer received honorarium from Novartis to participate in this event.

Professor Silvia Ferrucci Silvia ferrucci.png

Professor Silvia Ferrucci is Dermatologist-Venereologist and Head of Allergology Dermatology at Dermatology Foundation Clinic, Policlinico of Milan, Italy. Her areas of expertise include urticaria, atopic dermatitis and contact dermatitis. Professor Ferrucci is a member of the European Academy of Dermatology and Venereology (EADV) and was the Principal Investigator for a number of clinical trials. She has co-authored 76 peer-reviewed articles. 

Disclosures

This symposium is organised and funded by Novartis Pharma AG.

Professor Simon Francis Thomsen simon thomsen.png

Professor Simon Francis Thomsen is Dermatologist and Head of Dermato-Venereology at the Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark. His research focuses on aetiology, clinical course and treatment of chronic inflammatory skin diseases, including chronic urticaria. His interests include epidemiology, biomarkers and biologic/experimental treatment. Dr Thomsen is a Principal or Co-Investigator on several studies, and has co-authored 300 peer-reviewed articles.

Disclosures: This symposium is organised and funded by Novartis Pharma AG, Professor Simon Francis Thomsen received honorarium from Novartis to participate in this event. 

Novartis-sponsored symposium – Chronic Spontaneous Urticaria: Defining the pathway to successful management

In 2022, the European Academy of Allergy and Clinical Immunology (EAACI) celebrated its Annual Congress in Prague, Czech Republic

The Novartis-sponsored satellite symposium that featured at this year’s event focussed on ‘Chronic Spontaneous Urticaria: Defining the pathway to successful management’. This one-hour session was chaired by the renowned Professor Marcus Mauer, providing valuable insight into the evolving treatment landscape, exploration of the pain-points in the patient journey and how best to address them, and optimising patient management to address barriers to successful treatment.

Delays in diagnosing CSU and the importance of utilising PRO’s in successfully controlling CSU – a patient case study
Engagement of EAACI guidelines to step up and step down treatment, using omalizumab to control CSU
5

Professor Marcus Mauer began proceedings by offering insight into some of the major roadblocks in the successful management of CSU, including real-world data obtained from the CRUSE mobile application. This was followed by contributions from Professor Emek Kocatürk and Sinisa Savic, who discussed additional roadblocks and how to overcome them – primarily the delays in diagnosing CSU in patients, which can be alleviated by using patient-reported outcomes from the CRUSE app to aid in the diagnosis. These presentations were followed by a panel discussion into the use of omalizumab as part of adhering to updated EAACI 2022 guidelines.

Faculty

Marcus Maurer.pngProfessor Marcus Maurer

Professor Marcus Maurer is Professor of Dermatology and Allergy at the Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité – Universitätsmedizin Berlin, Germany.
He is also Director of Research at the Department of Dermatology and Allergy, Associate Director of the Allergie-Centrum-Charité, and Head of the Speciality Clinics for angioedema, hereditary angioedema, urticaria, mastocytosis, pruritis, auto-inflammatory disorders and the Dermatological Allergology Laboratory.
Disclosures: This symposium is organised and funded by Novartis Pharma AG, Professor Marcus Maurer received honorarium from Novartis to participate in this event.

Professor Emek Kocatürk.pngProfessor Emek Kocatürk

Professor Emek Kocatürk is a Professor of Urticaria Specialist and Dermatologist at Koç University, Istanbul, Turkey with clinical experience in treating chronic urticaria patients.
Her research interests focus on treatment responses, clinical phenotypes, management during pregnancy, patient-reported outcome measures, and inducible urticarias.
Disclosures: This symposium is organised and funded by Novartis Pharma AG, Professor Emek Kocatürk received honorarium from Novartis to participate in this event.

Professor Sinisa Savic.pngProfessor Sinisa Savic

Professor Sinisa Savic is a Professor at the University of Leeds, and honorary consultant immunologist based at St James’s University Hospital, Leeds, UK (United Kingdom) where he leads the Department of Clinical Immunology and Allergy.
Professor Savic was a Principal Investigator on the AWARE study, which investigated utilization of healthcare resources and quality of life in patients with CSU. He has an ongoing interest in optimizing the use of immunomodulatory therapies for the treatment of CSU.
Disclosures: This symposium is organised and funded by Novartis Pharma AG, Professor Sinisa Savic received honorarium from Novartis to participate in this event.

Novartis-sponsored symposium – Targeting complete CSU control: Current state of the art and future perspectives

In 2021, the European Academy of Dermatology and Venereology (EADV) celebrated its 30th Annual Congress

The Novartis-sponsored satellite symposium that featured at this year’s event focussed on ‘Targeting complete CSU control: Current state of the art and future perspectives’. This one-hour session was chaired by Professor Ana Giménez-Arnau, providing valuable insight into the evolving treatment landscape for CSU and the importance of treating the disease until it is gone.

Burden and unmet needs in chronic spontaneous urticaria
Novel treatment targets in chronic spontaneous urticaria
16

Professor Ana Giménez-Arnau kicked off proceedings by offering insight into some of the major unmet needs in CSU, including real-world data from the AWARE study. This was followed by contributions from Professor Sarbjit Saini and Dr John Reed, who discussed the development of novel anti-immunoglobulin E (anti-IgE) treatments for patients with chronic spontaneous urticaria and other potential therapeutic targets including Bruton’s tyrosine kinase (BTK) and Siglec-8.

Slides

Novartis-sponsored satellite symposium: Complete control of chronic spontaneous urticaria – Mission (im)possible?

In July 2021, the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress adopted a ‘hybrid’ format, combining digital and physical elements to produce an exciting and accessible scientific programme

This year’s Novartis company-sponsored virtual symposium, 'Complete control of chronic spontaneous urticaria – Mission (im)possible', was delivered by dermatology experts Professor Marcus Maurer and Professor Zenon Brzoza. In this 45-minute symposium the faculty discuss:

  • Why do our patients fail to reach complete control?
  • How can targeting IgE contribute to complete control?

Watch the full symposium video below. Use the chaptering buttons within the video to navigate to each section.


Despite the availability of effective therapeutic options and clear diagnostic and treatment algorithms for chronic spontaneous urticaria (CSU), many patients still fail to achieve complete control over their disease. In this symposium, the expert faculty offers insight into why this is the case and explain how the development of novel agents targeting IgE could help improve patient outcomes.

Expert interview

Short of time? In this brief interview, Professor Brzoza quizzes Professor Maurer on some of the key issues raised during his presentation at EAACI 2021.

Slides

Mind the PAF: a new route to managing chronic urticaria and allergic diseases?

The 1st European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress took place from 10–12 July 2021.

In 2021, for the first time, the EAACI Annual Congress adopted a “hybrid” format, offering delegates the opportunity to attend either digitally or physically, following the unprecedented success of the digital congress held in 2020. As ever, the congress was packed with unmissable scientific content that centred around the theme of ‘Harmonising research and patient care in allergy, asthma and clinical immunology’. This included a Uriach-sponsored symposium focussed on the role of platelet-activating factor (PAF) in chronic urticaria and allergic rhinitis, which you can watch below.

Welcome address

Symposium chair, Dr Frank Siebenhaar, introduces the expert faculty and outlines the agenda for this 1-hour session.

Introduction to PAF and PAF targeting treatments

Dr Frank Siebenhaar kicks-off the symposium with an overview of the role of PAF in the inflammatory allergy cascade and explains how H1/PAF blockers may be used in the treatment of allergic rhinitis and chronic urticarias.

Targeting PAF in allergic rhinitis: a responder analysis to rupatadine

Meet Armin, a 36-year-old patient who suffers from moderate-to-severe allergic rhinitis and nasal congestion. Could targeting PAF help relieve Armin’s symptoms? In this video, Professor Joaquim Mullol reviews current evidence regarding the efficacy of PAF inhibition in patients with seasonal and perennial allergic rhinitis.

Targeting PAF in chronic spontaneous urticaria: a success story

Dr Ana Giménez-Arnau uses a patient case study to illustrate the successes of PAF-targeting agents in patients with chronic spontaneous urticaria with a focus on new data which links PAF levels to CSU in patients who are refractory to treatment with antihistamines.

Panel discussion

Chaired by Dr Frank Siebenhaar, the expert panel address questions submitted by their live audience, diving a little deeper into each of their topics.

Ana Gimenez-Arnau.png
Dr Ana Giménez-Arnau. Associate Professor of Dermatology at the Universitat Autònoma and Pompeu Fabra of Barcelona and consultant Physician in Dermatology and Venereology in the Department of Dermatology at the Hospital del Mar.

Dr Frank Siebenhaar.png
Dr Frank Siebenhaar
Frank Siebenhaar is Assistant Professor at the Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité – Universitätsmedizin Berlin. He is Head of the Allergy Inpatient Care Unit and Mastocytosis Outpatient Clinic at the Department of Dermatology and coordinator of the Interdisciplinary Mastocytosis Centre at Charité. His main research interest lies in mast cell biology and the pathophysiology of mast cell-driven disease.

Professor Joaquim Mullol.png
Professor Joaquim Mullol
Joaquim Mullol is Professor of Research at the Universitat de Barcelona, Director of the Rhinology and Smell Clinic at the ENT Department of Hospital Clínic and Head of the Laboratory of Clinical and Experimental Respiratory Immunoallergy at the Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) in Barcelona, Spain. His main research interests lie in the mechanisms of upper airway inflammation.

Welcome:

Novartis-sponsored symposium: Redefining patient care in chronic spontaneous urticaria

The 29th European Academy of Dermatology and Venereology (EADV) Congress “EADV Virtual – New Frontiers in Dermatology and Venereology” took place between the 29–31 October 2020

Despite the challenges of transforming the EADV congress into a virtual event, the organisers remained dedicated to their mission of advancing excellence in clinical care, research, education, and training in the field of dermatology and venereology. Presentations from the Novartis company-sponsored virtual symposium ‘Redefining patient care in chronic spontaneous urticaria' can be found below.

Chair Professor Marcus Maurer, opened the symposium with an introduction to emerging endotypes of chronic spontaneous urticaria (CSU). He was joined by Dr Ana Giménez-Arnau who shared some of the key results from the global AWARE study, and Dr Alexander Eggel provided novel insights on the molecular and cellular level characteristics of different anti-IgE antibody treatments for CSU. Professor Maurer closed the symposium with a summary of the key data from a recent phase IIb clinical trial investigating the anti-IgE antibody, ligelizumab, for the treatment of patients whose disease was inadequately controlled by standard-of-care therapy. 

Q&A Session

In this informative session, the expert panel address some of the questions raised by the audience and provide further insight on the topics covered in each of their presentations.

EADV Presentations 2020

06–08 June 2020: Bridging innovations into allergy and asthma prevention

The first ever digital European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress was held between 6–8 June 2020. This completely new format was consistent with the aim of the meeting which was to push the boundaries with forward thinking and novel approaches to preventing allergy and asthma worldwide

EAACI encourages tackling allergic diseases and asthma at their root, and key to this was the Novartis company-sponsored virtual symposium ‘Breakthrough in the understanding of the anti-IgE pathway in CSU’, co-chaired by Professor Marcus Maurer and Dr. Alexander Eggel. Professor Maurer begins with an introduction to chronic spontaneous urticaria (CSU) and then hands over to Dr Eggel who speaks in detail about IgE inhibition in CSU, explaining why not all anti-IgEs are born equal. Professor Maurer then describes the clinical implications of this inequality which helps to explain the differential effects of omalizumab and ligelizumab in CSU and asthma.

Following the symposium, the faculty were interviewed on their symposium topics. Discover this additional insight in the expert interview section following the symposium presentations.

IgE inhibition clinical implications
15

Put your knowledge to the test with interactive eLearning modules focussed on understanding the role of the IgE pathway in the inflammatory process that leads to the development of the symptoms in CSU, and the potential benefits of IgE inhibition

 

Expert interviews

Following the symposium, Professor Maurer and Dr Eggel were asked a series of questions to delve deeper into their presentation topics.

Welcome:

Developed by EPG Health for Medthority. The EADV 2022 symposium is developed in collaboration with Novartis Pharma AG and expert faculty. All other symposia have been developed in collaboration with Novartis Pharma AG, J. Uriach y Compañía S.A and expert faculty. EPG Health received funding from Novartis Pharma AG in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. The views presented in the videos are those of the presenters and not necessarily those of the industry sponsor, Novartis Pharma AG. Any data on non- Novartis products are based on publicly available information at the time of content update. Prescribing information may vary depending on local health authority approval in each country. Before prescribing any product, always refer to the SmPC or product information approved in your local country.